A Phase 2, Randomized, 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Degarelix (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 05 Apr 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 05 Apr 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.